Efficacy and safety of aspirin in patients with peripheral vascular disease: An updated systematic review and meta-analysis of randomized controlled trials

PLoS ONE

Volumn 12, Issue 4, 2017, Pages

  Mahmoud, Ahmed N ^a   Elgendy, Akram Y ^a   Rambarat, Cecil ^a   Mahtta, Dhruv ^a   Elgendy, Islam Y ^a   Bavry, Anthony A ^a,b  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA TOCOPHEROL; ANTIOXIDANT; PLACEBO; FIBRINOLYTIC AGENT;

ALL CAUSE MORTALITY; ARTERY DISEASE; ARTICLE; BLEEDING; BRAIN HEMORRHAGE; CEREBROVASCULAR ACCIDENT; CEREBROVASCULAR DISEASE; DRUG EFFICACY; DRUG SAFETY; EVIDENCE BASED MEDICINE; HEART DISEASE; HEART INFARCTION; HUMAN; LEG ISCHEMIA; LOW DRUG DOSE; META ANALYSIS; MORTALITY; OUTCOME ASSESSMENT; PERIPHERAL VASCULAR DISEASE; PRACTICE GUIDELINE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMATIC REVIEW; CHEMICALLY INDUCED; COMPLICATION; MYOCARDIAL INFARCTION; PERIPHERAL VASCULAR DISEASES; STROKE; TREATMENT OUTCOME;

ASPIRIN; FIBRINOLYTIC AGENTS; HEMORRHAGE; HUMANS; INTRACRANIAL HEMORRHAGES; MYOCARDIAL INFARCTION; PERIPHERAL VASCULAR DISEASES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; STROKE; TREATMENT OUTCOME;

EID: 85017456625     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0175283     Document Type: Article

References (34)

1. Fowkes FG, Rudan D, Rudan I, Aboyans V, Denenberg JO, McDermott MM, et al. Comparison of global estimates of prevalence and risk factors for peripheral artery disease in 2000 and 2010: a systematic review and analysis. Lancet. 2013; 382: 1329-1340. https://doi.org/10.1016/S0140-6736(13)61249-0 PMID: 23915883
2. Gerhard-Herman MD, Gornik HL, Barrett C, Barshes NR, Corriere MA, Drachman DE, et al. 2016 AHA/ACC Guideline on the Management of Patients With Lower Extremity Peripheral Artery Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2016 Nov 8. pii: S0735-1097(16)36903-0.
3. Alonso-Coello P, Bellmunt S, McGorrian C, Anand SS, Guzman R, Criqui MH, et al. Antithrombotic therapy in peripheral artery disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012; 141(2 Suppl): e669S-90S. https://doi.org/10.1378/chest.11-2307 PMID: 22315275
4. Collaborative overview of randomised trials of antiplatelet therapy - I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration. BMJ. 1994; 308: 81-106. PMID: 8298418
5. Secondary prevention of vascular disease by prolonged antiplatelet treatment. Antiplatelet Trialists' Collaboration. Br Med J (Clin Res Ed). 1988; 296: 320-331.
6. Bavry AA, Gong Y, Handberg EM, Cooper-DeHoff RM, Pepine CJ. Impact of aspirin according to type of stable coronary artery disease: insights from a large international cohort. Am J Med. 2015; 128: 137-143. https://doi.org/10.1016/j.amjmed.2014.09.028 PMID: 25447610
7. Berger JS, Krantz MJ, Kittelson JM, Hiatt WR. Aspirin for the prevention of cardiovascular events in patients with peripheral artery disease: a meta-analysis of randomized trials. JAMA. 2009; 301: 1909-1919. https://doi.org/10.1001/jama.2009.623 PMID: 19436018
8. Robless P, Mikhailidis DP, Stansby G. Systematic review of antiplatelet therapy for the prevention of myocardial infarction, stroke or vascular death in patients with peripheral vascular disease. Br J Surg. 2001; 88: 787-800. https://doi.org/10.1046/j.0007-1323.2001.01774.x PMID: 11412247
9. Baigent C, Blackwell L, Collins R, Emberson J, Godwin J, Peto R, et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet. 2009; 373: 1849-1860. https://doi.org/10.1016/S0140-6736(09)60503-1 PMID: 19482214
10. Fowkes FG, Price JF, Stewart MC, Butcher I, Leng GC, Pell AC, et al. Aspirin for prevention of cardiovascular events in a general population screened for a low ankle brachial index: a randomized controlled trial. JAMA. 2010; 303: 841-848. https://doi.org/10.1001/jama.2010.221 PMID: 20197530
11. Jones WS, Baumgartner I, Hiatt WR, Heizer G, Conte MS, White CJ, et al. Ticagrelor compared with clopidogrel in patients with prior lower extremity revascularization for peripheral artery disease. Circulation. 2017; 135: 241-250. https://doi.org/10.1161/CIRCULATIONAHA.116.025880 PMID: 27840336
12. Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 2009; 339: b2535. https://doi.org/10.1136/bmj.b2535 PMID: 19622551
13. Higgins JP, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ. 2011; 343: d5928. https://doi.org/10. 1136/bmj.d5928 PMID: 22008217
14. Atkins D, Best D, Briss PA, Eccles M, Falck-Ytter Y, Flottorp S, et al. Grading quality of evidence and strength of recommendations. BMJ. 2004; 328: 1490. https://doi.org/10.1136/bmj.328.7454.1490 PMID: 15205295
15. Nyaga VN, Arbyn M, Aerts M. Metaprop: a Stata command to perform meta-analysis of binomial data. Arch Public Health. 2014; 72: 39. https://doi.org/10.1186/2049-3258-72-39 PMID: 25810908
16. Arbyn M, Martin-Hirsch P, Buntinx F, Van Ranst M, Paraskevaidis E, Dillner J. Triage of women with equivocal or low-grade cervical cytology results: a meta-analysis of the HPV test positivity rate. J Cell Mol Med. 2009; 13: 648-659. https://doi.org/10.1111/j.1582-4934.2008.00631.x PMID: 19166485
17. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986; 7: 177-188. PMID: 3802833
18. Yusuf S, Peto R, Lewis J, Collins R, Sleight P. Beta blockade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Dis. 1985; 27: 335-371. PMID: 2858114
19. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003; 327: 557-560. https://doi.org/10.1136/bmj.327.7414.557 PMID: 12958120
20. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997; 315: 629-634. PMID: 9310563
21. Belch J, MacCuish A, Campbell I, Cobbe S, Taylor R, Prescott R, et al. The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease. BMJ. 2008; 337: a1840. https://doi.org/10.1136/bmj.a1840 PMID: 18927173
22. Catalano M, Born G, Peto R, Critical Leg Ischaemia Prevention Study (CLIPS) Group. Prevention of serious vascular events by aspirin amongst patients with peripheral arterial disease: randomized, double-blind trial. J Intern Med. 2007; 261: 276-284. https://doi.org/10.1111/j.1365-2796.2006.01763.x PMID: 17305650
23. Hess H, Mietaschk A, Deichsel G. Drug-induced inhibition of platelet function delays progression of peripheral occlusive arterial disease. A prospective double-blind arteriographically controlled trial. Lancet. 1985; 1: 415-419. PMID: 2857803
24. Lassila R, Lepäntalo M, Lindfors O. The effect of acetylsalicylic acid on the outcome after lower limb arterial surgery with special reference to cigarette smoking. World J Surg. 1991; 15: 378-382. PMID: 1853617
25. Green RM, Roedersheimer LR, DeWeese JA. Effects of aspirin and dipyridamole on expanded polytetrafluoroethylene graft patency. Surgery. 1982; 92: 1016-1626. PMID: 6755786
26. Harajola PT, Meurala H, Frick MH. Prevention of early reocclusion by dipyridamole and ASA in arterial reconstructive surgery. J Cardiovasc Surg (Torino). 1981; 22: 141-144.
27. Roztocil K, Oliva I, Prerovský I, Linhart J. The effect of hydroxyethylrutoside and its combination with acetylsalicylic acid in patients with obliterative atherosclerosis. Cor Vasa. 1989; 31: 128-133. PMID: 2663343
28. Ehresmann U, Alemany J, Loew D. [Use of acetylsalicylic acid in the prevention of re-occlusion following revascularization interventions. Results of a double-blind long term study]. Med Welt. 1977; 28: 1157-1162. PMID: 886967
29. Hess H and Keil-Kuri E. Theoretische grundlagen der prophylaxe obliterierender arteriopathien mit aggregationshemmern und ergebnisse einer langzeitstudie mit ASS (Colfarit). In: Marx R, Breddin HK, eds. Proceedings of Colfarit Symposium III. Köln, Germany: Bayer; 1975: 80-87.
30. Zekert F. Klinische anwendung von aggregationshemmern bei arterieller verschluûkrankheit. In: Zekert F, ed. Thrombosen, Embolien und Aggregationshemmer in der Chirurgie. Stuttgart, Germany: Schattauer; 1975: 68-72.
31. Fowkes FG, Murray GD, Butcher I, Heald CL, Lee RJ, Chambless LE, et al. Ankle brachial index combined with Framingham Risk Score to predict cardiovascular events and mortality: a meta-analysis. JAMA. 2008; 300: 197-208. https://doi.org/10.1001/jama.300.2.197 PMID: 18612117
32. Campbell CL, Smyth S, Montalescot G, Steinhubl SR. Aspirin dose for the prevention of cardiovascular disease: a systematic review. JAMA. 2007; 297: 2018-2024. https://doi.org/10.1001/jama.297.18. 2018 PMID: 17488967
33. Bibbins-Domingo K; US Preventive Services Task Force. Aspirin use for the primary prevention of cardiovascular disease and colorectal cancer: U.S. Preventive Services Task Force Recommendation Statement. Ann Intern Med. 2016; 164: 836-845. https://doi.org/10.7326/M16-0577 PMID: 27064677
34. Ferrari E, Benhamou M, Cerboni P, Marcel B. Coronary syndromes following aspirin withdrawal: a special risk for late stent thrombosis. J Am Coll Cardiol. 2005; 45: 456-459. https://doi.org/10.1016/j.jacc. 2004.11.041 PMID: 15680728